Despite the lack of overlap in input gene signatures, all three DMEA analyses correctly identified EGFR inhibitors as the top toxic drug MOA for the EGFR inhibitor-sensitive cancer cell lines (Fig. 6A,B, Additional file 1: Fig. S5). Here, EGFR is linked to cancer.